Effect of <i>Bombyx mori</i> on the Liver Protection of Non-Alcoholic Fatty Liver Disease Based on In Vitro and In Vivo Models

• Main Authors: Miey Park, Chaewon Kang, Hae-Jeung Lee
• Format: Article
• Language: English
• Published: MDPI AG 2021-04-01
• Series: Current Issues in Molecular Biology
• Subjects: <i>Bombyx mori</i> (silkworm); non-alcoholic fatty liver disease (NAFLD); AMP-activated protein kinase (AMPK); acetyl-CoA carboxylase (ACC)
• Online Access: https://www.mdpi.com/1467-3045/43/1/3

Edible insects, <i>Bombyx mori</i> (silkworm; SW), which feed on mulberry leaves, have been consumed by humans for a long time as supplements or traditional medication. Non-alcoholic fatty liver disease (NAFLD) is a liver metabolic disorder that affects many people worldwide. We examined the hepatoprotective effects of SW using in vitro and high-fat and high-fructose (HFHF) diet-induced obese in vivo model mice by real-time PCR, immunoblot analysis, and fecal microbiota analysis. SW significantly reduced lipid accumulation and expression of the lipogenic genes in HepG2 cells and the livers of HFHF-induced mice. SW caused significant reductions in triglycerides, and total cholesterol in serum and upregulation of fatty acid oxidation markers compared to the HFHF group. Besides, SW significantly induced phosphorylation of AMPK and ACC in both models, suggesting roles in AMPK activation and the ACC signaling pathway. Furthermore, the gut microbiota analysis demonstrated that SW treatment reduced Firmicutes to Bacteroidetes ratios and the relative abundance of the Lachnospiraceae family compared to HFHF-induced obese mice. These results provide a novel therapeutic agent of hepatoprotective effects of SW for non-alcoholic hepatic steatosis that targets hepatic AMPK and ACC-mediated lipid metabolism.